LLY vs. CLS
LLY (Eli Lilly and Company) and CLS (Celestica Inc.) are both stocks. LLY operates in Drug Manufacturers - General (Healthcare), while CLS operates in Electronic Components (Technology). Over the past 10 years, LLY returned 33.45%/yr vs 43.71%/yr for CLS. At a 0.20 correlation, their price movements are largely independent.
Performance
LLY vs. CLS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, LLY achieves a 5.78% return, which is significantly lower than CLS's 32.99% return. Over the past 10 years, LLY has underperformed CLS with an annualized return of 33.45%, while CLS has yielded a comparatively higher 43.71% annualized return.
LLY
- 1D
- -2.41%
- 1M
- 12.75%
- YTD
- 5.78%
- 6M
- 10.64%
- 1Y
- 39.26%
- 3Y*
- 37.45%
- 5Y*
- 39.59%
- 10Y*
- 33.45%
CLS
- 1D
- 1.88%
- 1M
- 9.64%
- YTD
- 32.99%
- 6M
- 28.26%
- 1Y
- 213.67%
- 3Y*
- 207.28%
- 5Y*
- 116.26%
- 10Y*
- 43.71%
LLY vs. CLS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
LLY Eli Lilly and Company | 5.78% | 40.25% | 33.30% | 60.91% | 34.26% | 66.08% | 31.04% | 16.14% | 40.45% | 17.83% |
CLS Celestica Inc. | 32.99% | 220.27% | 215.23% | 159.80% | 1.26% | 37.92% | -2.42% | -5.70% | -16.32% | -11.56% |
Correlation
The correlation between LLY and CLS is -0.03, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.03 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.14 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.14 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.14 |
Correlation (All Time) Calculated using the full available price history since Jun 30, 1998 | 0.20 |
The correlation between LLY and CLS shifts across timeframes, from -0.03 (1 year) to 0.20 (all time), reflecting how their relationship changes across market environments.
Fundamentals
LLY:
$1.02T
CLS:
$45.48B
LLY:
$28.14
CLS:
$8.28
LLY:
40.26
CLS:
47.45
LLY:
0.81
CLS:
0.64
LLY:
14.08
CLS:
3.30
LLY:
32.54
CLS:
21.68
LLY:
$72.25B
CLS:
$13.81B
LLY:
$59.75B
CLS:
$1.60B
LLY:
$32.97B
CLS:
$1.32B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
LLY vs. CLS — Risk / Return Rank
LLY
CLS
LLY vs. CLS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Eli Lilly and Company (LLY) and Celestica Inc. (CLS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| LLY | CLS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.71 | ||
| Sortino ratioReturn per unit of downside risk | -1.18 | ||
| Omega ratioGain probability vs. loss probability | 1.22 | 1.37 | -0.15 |
| Calmar ratioReturn relative to maximum drawdown | 1.72 | 6.91 | -5.19 |
| Martin ratioReturn relative to average drawdown | 4.28 | 16.83 | -12.55 |
Loading charts...
Drawdowns
LLY vs. CLS - Drawdown Comparison
The maximum LLY drawdown since its inception was -68.24%, smaller than the maximum CLS drawdown of -96.93%. Use the drawdown chart below to compare losses from any high point for LLY and CLS.
Loading charts...
Drawdown Indicators
| LLY | CLS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -68.24% | -96.93% | +28.69% |
Max Drawdown (1Y)Largest decline over 1 year | -23.64% | -29.24% | +5.60% |
Max Drawdown (3Y)Largest decline over 3 years | -34.48% | -53.96% | +19.48% |
Max Drawdown (5Y)Largest decline over 5 years | -34.48% | -53.96% | +19.48% |
Max Drawdown (10Y)Largest decline over 10 years | -34.48% | -80.60% | +46.12% |
Current DrawdownCurrent decline from peak | -2.41% | -16.78% | +14.37% |
Average DrawdownAverage peak-to-trough decline | -19.21% | -73.31% | +54.10% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.49% | 11.98% | -2.49% |
Volatility
LLY vs. CLS - Volatility Comparison
The current volatility for Eli Lilly and Company (LLY) is 9.27%, while Celestica Inc. (CLS) has a volatility of 27.54%. This indicates that LLY experiences smaller price fluctuations and is considered to be less risky than CLS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| LLY | CLS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.27% | 27.54% | -18.27% |
Volatility (6M)Calculated over the trailing 6-month period | 27.16% | 55.42% | -28.26% |
Volatility (1Y)Calculated over the trailing 1-year period | 38.01% | 72.65% | -34.64% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 32.46% | 57.70% | -25.24% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 30.19% | 49.97% | -19.78% |
Dividends
LLY vs. CLS - Dividend Comparison
LLY's dividend yield for the trailing twelve months is around 0.57%, while CLS has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CLS Celestica Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LLY Eli Lilly and Company | 0.57% | 0.56% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.94% | 2.46% | 2.77% | 2.37% |
Financials
LLY vs. CLS - Financials Comparison
This section allows you to compare key financial metrics between Eli Lilly and Company and Celestica Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
LLY vs. CLS - Profitability Comparison
LLY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Eli Lilly and Company reported a gross profit of 15.64B and revenue of 19.80B. Therefore, the gross margin over that period was 79.0%.
CLS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported a gross profit of 437.20M and revenue of 4.05B. Therefore, the gross margin over that period was 10.8%.
LLY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Eli Lilly and Company reported an operating income of 9.19B and revenue of 19.80B, resulting in an operating margin of 46.4%.
CLS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported an operating income of 272.10M and revenue of 4.05B, resulting in an operating margin of 6.7%.
LLY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Eli Lilly and Company reported a net income of 7.40B and revenue of 19.80B, resulting in a net margin of 37.4%.
CLS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported a net income of 212.30M and revenue of 4.05B, resulting in a net margin of 5.3%.
Frequently Asked Questions
LLY and CLS have a correlation of -0.03, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CLS has higher volatility (27.54%) compared to LLY (9.27%). In terms of maximum drawdown, LLY dropped -68.24% vs CLS's -96.93%.
CLS currently has the higher Sharpe Ratio (2.78 vs 1.07), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for LLY and CLS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer